The European Commission (EC) has authorized rucaparib as monotherapy treatment of adult patients with platinum-sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary...
More From BioPortfolio on "European Commission issues authorisation of rucaparib for women with recurrent ovarian cancer"